Huizenga Theodore Alan — SEC insider filings

SEC reporting owner CIK 1603347. 32 insider filings on record with FilingPulse; latest filed 2026-09-15.

Transaction summary — filings shown

Covers all 32 filings on record, filed 2020-10-16 to 2026-09-15. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Ultragenyx Pharmaceutical Inc. (RARE)SVP, Chief Accounting Officer32—24 legs · 19,746 sh · $1,507,79435

Insider filings — Huizenga Theodore Alan

FiledFormIssuerReported transactionsSource
2026-09-154Ultragenyx Pharmaceutical Inc. (RARE)Sale (S): 1,283 @ $13.57EDGAR
2026-09-084Ultragenyx Pharmaceutical Inc. (RARE)Sale (S): 161 @ $13.99EDGAR
2026-04-244Ultragenyx Pharmaceutical Inc. (RARE)Grant/award (A): 20,241 @ $0 · Grant/award (A): 7,348 (derivative) @ $0EDGAR
2026-03-034Ultragenyx Pharmaceutical Inc. (RARE)Tax withholding (F): 148 @ $23.39 · Sale (S): 1,632 @ $22.80EDGAR
2025-12-304Ultragenyx Pharmaceutical Inc. (RARE)Sale (S): 85 @ $34.38EDGAR
2025-09-194Ultragenyx Pharmaceutical Inc. (RARE)Sale (S): 64 @ $29.17EDGAR
2025-09-084Ultragenyx Pharmaceutical Inc. (RARE)Sale (S): 84 @ $31.39EDGAR
2025-03-044Ultragenyx Pharmaceutical Inc. (RARE)Grant/award (A): 9,392 @ $0 · Sale (S): 967 @ $42.10 · Tax withholding (F): 141 @ $42.92 · Grant/award (A): 5,632 (derivative) @ $0EDGAR
2024-12-114Ultragenyx Pharmaceutical Inc. (RARE)Gift (G): 648 @ $0EDGAR
2024-09-184Ultragenyx Pharmaceutical Inc. (RARE)Grant/award (A): 700 @ $0EDGAR
2024-09-054Ultragenyx Pharmaceutical Inc. (RARE)Sale (S): 91 @ $56.19EDGAR
2024-04-184Ultragenyx Pharmaceutical Inc. (RARE)Tax withholding (F): 14 @ $42.31EDGAR
2024-03-054Ultragenyx Pharmaceutical Inc. (RARE)Grant/award (A): 13,950 @ $0 · Tax withholding (F): 121 @ $53.69 · Sale (S): 341 @ $53.76 · Grant/award (A): 8,200 (derivative) @ $0 · Grant/award (A): 2,351 (derivative) @ $0EDGAR
2024-01-024Ultragenyx Pharmaceutical Inc. (RARE)Grant/award (A): 1,000 @ $0 · Option exercise (M): 3,000 @ $21 · Option exercise (M): 3,000 (derivative) @ $0EDGAR
2023-09-294Ultragenyx Pharmaceutical Inc. (RARE)Grant/award (A): 2,351 (derivative) @ $0EDGAR
2023-09-114Ultragenyx Pharmaceutical Inc. (RARE)Option exercise (M): 2,000 @ $21 · Sale (S): 2,000 @ $41 · Sale (S): 163 @ $38.34 · Option exercise (M): 2,000 (derivative) @ $0EDGAR
2023-09-064Ultragenyx Pharmaceutical Inc. (RARE)Sale (S): 883 @ $37.04 · Sale (S): 87 @ $38.23EDGAR
2023-05-104Ultragenyx Pharmaceutical Inc. (RARE)Option exercise (M): 3,000 @ $21 · Option exercise (M): 3,000 (derivative) @ $0EDGAR
2023-04-184Ultragenyx Pharmaceutical Inc. (RARE)Tax withholding (F): 14 @ $38.20 · Disposition to issuer (D): 181 @ $38.20EDGAR
2023-03-034Ultragenyx Pharmaceutical Inc. (RARE)Grant/award (A): 7,590 @ $0 · Sale (S): 100 @ $45.65 · Disposition to issuer (D): 1,333 @ $45.65 · Grant/award (A): 10,120 (derivative) @ $0EDGAR
2023-03-024Ultragenyx Pharmaceutical Inc. (RARE)Sale (S): 639 @ $43.40EDGAR
2022-12-224Ultragenyx Pharmaceutical Inc. (RARE)Sale (S): 2,031 @ $43.96EDGAR
2022-09-084Ultragenyx Pharmaceutical Inc. (RARE)Grant/award (A): 1,000 @ $0EDGAR
2022-04-194Ultragenyx Pharmaceutical Inc. (RARE)Sale (S): 132 @ $84.55EDGAR
2022-03-034Ultragenyx Pharmaceutical Inc. (RARE)Sale (S): 843 @ $66.62 · Grant/award (A): 3,710 @ $0 · Grant/award (A): 7,400 (derivative) @ $0EDGAR
2021-10-184Ultragenyx Pharmaceutical Inc. (RARE)Gift (G): 819 @ $0 · Sale (S): 140 @ $81.14EDGAR
2021-05-104Ultragenyx Pharmaceutical Inc. (RARE)Sale (S): 142 @ $113.67EDGAR
2021-04-194Ultragenyx Pharmaceutical Inc. (RARE)Grant/award (A): 1,500 @ $0EDGAR
2021-03-094Ultragenyx Pharmaceutical Inc. (RARE)Sale (S): 3,000 @ $120.69EDGAR
2021-03-034Ultragenyx Pharmaceutical Inc. (RARE)Grant/award (A): 1,560 @ $0 · Sale (S): 732 @ $138.17 · Grant/award (A): 4,655 (derivative) @ $0EDGAR
2021-01-084Ultragenyx Pharmaceutical Inc. (RARE)Option exercise (M): 4,000 @ $21 · Sale (S): 4,000 @ $140.65 · Option exercise (M): 4,000 (derivative) @ $0EDGAR
2020-10-164Ultragenyx Pharmaceutical Inc. (RARE)Sale (S): 146 @ $87.98EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-10-16 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1603347 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs